This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Venlafaxine: Loss of Antidepressant Effect and Its Management

Verinder Sharma

Published: July 15, 1998

Article Abstract

Sir: The antidepressant profile of venlafaxine includes a broad range of clinical activity, as its effect is not influenced by factors such as the presence of melancholic features, age, gender, severity, or duration of depression. A recent analysis of the treatments of major depression revealed that venlafaxine had the highest efficacy rates and lowest dropout rates when compared with tricyclics and serotonin reuptake inhibitors. Up to one third of patients with rigorously defined treatmentresistant depression show a favorable response to venlafaxine, but nearly half of these patients are unable to sustain the antidepressant effect during the first 3 months of treatment.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 59

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...